Vitae Pharmaceuticals Company Profile (NASDAQ:VTAE)

About Vitae Pharmaceuticals

Vitae Pharmaceuticals logoVitae Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company's product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Company completed approximately two Phase I studies with VTP-43742. Its VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. Its VTP-36951 is for the treatment and prevention of Alzheimer's disease, or Alzheimer's. VTP-43742, the Company's wholly owned clinical candidate in an on-going Phase IIa proof-of-concept trial in psoriasis, is an orally active small molecule inhibitor of Retinoic acid-receptor (RAR)-Related Orphan Receptor gamma-t (RORgt) activity for the treatment of various autoimmune disorders.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VTAE
  • CUSIP:
Key Metrics:
  • Previous Close: $7.14
  • 50 Day Moving Average: $9.73
  • 200 Day Moving Average: $8.52
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.76
  • P/E Growth: 0.00
  • Market Cap: $205.92M
  • Outstanding Shares: 28,841,000
  • Beta: 1
Additional Links:
Companies Related to Vitae Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Vitae Pharmaceuticals (NASDAQ:VTAE) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $19.00 (166.11% upside)

Analysts' Ratings History for Vitae Pharmaceuticals (NASDAQ:VTAE)
Show:
DateFirmActionRatingPrice TargetDetails
8/4/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
8/3/2016WedbushReiterated RatingOutperform$23.00View Rating Details
6/10/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
4/11/2016BMO Capital MarketsInitiated CoverageOutperform$15.00View Rating Details
3/20/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details
3/17/2016Stifel NicolausUpgradeHold -> Buy$15.00View Rating Details
(Data available from 8/25/2014 forward)

Earnings

Earnings History for Vitae Pharmaceuticals (NASDAQ:VTAE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/3/2016Q2($0.41)($0.36)ViewListenView Earnings Details
5/10/2016Q1($0.51)($0.44)$0.05 millionViewListenView Earnings Details
3/3/2016Q415($0.62)($0.52)$0.14 million$0.09 millionViewListenView Earnings Details
11/5/2015Q315($0.48)($0.60)$0.18 million$0.18 millionViewListenView Earnings Details
8/4/2015Q215($0.45)($0.45)$0.09 million$0.16 millionViewListenView Earnings Details
5/13/2015Q115($0.33)($0.47)$0.08 millionViewListenView Earnings Details
3/31/2015Q414($0.45)($0.40)$0.19 million$0.16 millionViewListenView Earnings Details
11/12/2014Q3($0.13)($1.03)$6.39 million$6.18 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vitae Pharmaceuticals (NASDAQ:VTAE)
Current Year EPS Consensus Estimate: $-1.66 EPS
Next Year EPS Consensus Estimate: $-1.9 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.39)($0.39)($0.39)
Q2 20161($0.35)($0.35)($0.35)
Q3 20161($0.35)($0.35)($0.35)
Q4 20161($0.34)($0.34)($0.34)
Q1 20171($0.34)($0.34)($0.34)
Q2 20171($0.34)($0.34)($0.34)
Q3 20171($0.32)($0.32)($0.32)
Q4 20171($0.29)($0.29)($0.29)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Vitae Pharmaceuticals (NASDAQ:VTAE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Vitae Pharmaceuticals (NASDAQ:VTAE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/21/2016Donald J Hayden JrDirectorSell16,130$7.42$119,684.60View SEC Filing  
12/29/2015Donald J. Hayden, Jr.DirectorSell16,130$18.00$290,340.00View SEC Filing  
12/23/2015Jeffrey S. HatfieldCEOSell22,524$17.00$382,908.00View SEC Filing  
9/21/2015Donald J. Hayden, Jr.DirectorSell16,130$17.00$274,210.00View SEC Filing  
9/29/2014Peter BarrettDirectorBuy37,500$8.00$300,000.00View SEC Filing  
9/29/2014Venrock Management Iii LlcMajor ShareholderBuy772,333$8.00$6,178,664.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Vitae Pharmaceuticals (NASDAQ:VTAE)
DateHeadline
News IconStock Tracking Lower for the Quarter: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Post News (NASDAQ:VTAE)
www.kentuckypostnews.com - August 21 at 6:59 AM
News IconCrowd Sentiment & Wall Street Views on Vitae Pharmaceuticals, Inc ... - Post News (NASDAQ:VTAE)
www.kentuckypostnews.com - August 17 at 11:07 AM
insidermonkey.com logoVitae Pharmaceuticals Inc (VTAE): RA Capital Management Ups Its Stake (NASDAQ:VTAE)
www.insidermonkey.com - August 16 at 11:33 AM
finance.yahoo.com logoVITAE PHARMACEUTICALS, INC Financials (NASDAQ:VTAE)
finance.yahoo.com - August 13 at 7:41 PM
publicnow.com logoVitae Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference (NASDAQ:VTAE)
www.publicnow.com - August 11 at 11:39 AM
publicnow.com logoVitae Pharmaceuticals Appoints Scott Applebaum as General Counsel and Corporate Secretary (NASDAQ:VTAE)
www.publicnow.com - August 10 at 8:53 PM
capitalcube.com logoETF’s with exposure to Vitae Pharmaceuticals, Inc. : August 8, 2016 (NASDAQ:VTAE)
www.capitalcube.com - August 8 at 8:23 PM
seekingalpha.com logoVitae Pharmaceuticals' (VTAE) CEO Jeffrey Hatfield on Q2 2016 Results - Earnings Call Transcript - Seeking Alpha (NASDAQ:VTAE)
seekingalpha.com - August 6 at 8:03 PM
ftsenews.co.uk logoNew Broker Ratings For Vitae Pharmaceuticals, Inc. (VTAE) - FTSE ... - FTSE News (NASDAQ:VTAE)
www.ftsenews.co.uk - August 5 at 8:25 PM
capitalcube.com logoVitae Pharmaceuticals, Inc. :VTAE-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 (NASDAQ:VTAE)
www.capitalcube.com - August 5 at 8:25 PM
twst.com logoVitae Pharmaceuticals Inc.: Vitae Pharmaceuticals Reports Second Quarter 2016 Operating and Financial Results (NASDAQ:VTAE)
www.twst.com - August 4 at 8:41 PM
finance.yahoo.com logoVitae Pharmaceuticals downgraded by JMP Securities (NASDAQ:VTAE)
finance.yahoo.com - August 4 at 8:41 PM
finance.yahoo.com logoEdited Transcript of VTAE earnings conference call or presentation 3-Aug-16 8:30pm GMT (NASDAQ:VTAE)
finance.yahoo.com - August 4 at 8:41 PM
biz.yahoo.com logoVITAE PHARMACEUTICALS, INC Files SEC form 10-Q, Quarterly Report (NASDAQ:VTAE)
biz.yahoo.com - August 4 at 8:41 PM
globenewswire.com logoVitae Pharmaceuticals Reports Second Quarter 2016 Operating and Financial Results (NASDAQ:VTAE)
globenewswire.com - August 4 at 11:28 AM
globenewswire.com logoVitae Pharmaceuticals Reports Second Quarter 2016 Operating and Financial Results - GlobeNewswire (press release) (NASDAQ:VTAE)
globenewswire.com - August 3 at 8:35 PM
sg.finance.yahoo.com logoVitae Pharmaceuticals reports 2Q loss (NASDAQ:VTAE)
sg.finance.yahoo.com - August 3 at 8:35 PM
biz.yahoo.com logoQ2 2016 Vitae Pharmaceuticals Inc Earnings Release - Time Not Supplied (NASDAQ:VTAE)
biz.yahoo.com - August 3 at 11:33 AM
benzinga.com logoVitae Pharmaceuticals to Announce Second Quarter... (NASDAQ:VTAE)
www.benzinga.com - August 1 at 7:56 PM
publicnow.com logoVitae Pharmaceuticals to Announce Second Quarter 2016 Financial Results on August 3, 2016 (NASDAQ:VTAE)
www.publicnow.com - August 1 at 7:56 PM
globenewswire.com logoVitae Pharmaceuticals Appoints Daniel M. Junius to Board of Directors - GlobeNewswire (press release) (NASDAQ:VTAE)
www.globenewswire.com - July 28 at 11:35 AM
publicnow.com logoVitae Pharmaceuticals Appoints Daniel M. Junius to Board of Directors (NASDAQ:VTAE)
www.publicnow.com - July 27 at 4:58 PM
biz.yahoo.com logoVITAE PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex (NASDAQ:VTAE)
biz.yahoo.com - July 27 at 4:42 PM
News IconVitae Pharmaceuticals, Inc. (NASDAQ:VTAE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:VTAE)
www.engelwooddaily.com - July 23 at 11:30 AM
News IconVitae Pharmaceuticals Incorporated (NASDAQ:VTAE) Shorted Shares Increased By 1.36% - Consumer Eagle (NASDAQ:VTAE)
www.consumereagle.com - July 23 at 11:30 AM
News IconStock Moving Lower for the Month; Investor Update on Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Engelwood Daily (NASDAQ:VTAE)
www.engelwooddaily.com - July 21 at 8:33 PM
News IconVitae Pharmaceuticals Incorporated (NASDAQ:VTAE) Sellers Covered 8.81% of Their Shorts - Consumer Eagle (NASDAQ:VTAE)
www.consumereagle.com - July 19 at 9:07 AM
News IconAre Analysts Bullish Vitae Pharmaceuticals Inc (NASDAQ:VTAE) After Last Week? - Consumer Eagle (NASDAQ:VTAE)
www.consumereagle.com - July 18 at 7:11 AM
News IconShares Moving Down on the Week: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Engelwood Daily (NASDAQ:VTAE)
www.engelwooddaily.com - July 17 at 7:16 AM
News IconAnalyst Target and Average Rating Watch: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Press Telegraph (NASDAQ:VTAE)
presstelegraph.com - July 16 at 11:21 AM
News IconShares Experiencing a Downtrend: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - TGP (NASDAQ:VTAE)
telanaganapress.com - July 16 at 11:21 AM
News IconVitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:VTAE)
www.engelwooddaily.com - July 16 at 11:21 AM
news.cmlviz.com logoOption Market: Vitae Pharmaceuticals Inc Risk Hits An Elevated Level - CML News (NASDAQ:VTAE)
news.cmlviz.com - July 14 at 8:26 PM
News IconVitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Wall Street Analyst Recommendation Outlook - Telanagana Press (NASDAQ:VTAE)
telanaganapress.com - July 13 at 11:01 AM
News Icon2016 Q1 Sentiment Vitae Pharmaceuticals (NASDAQ:VTAE) - Consumer Eagle (NASDAQ:VTAE)
www.consumereagle.com - July 13 at 11:01 AM
News IconVitae Pharmaceuticals Incorporated (NASDAQ:VTAE) Shorts Decreased by 8.81% After Short Covering - Press Telegraph (NASDAQ:VTAE)
presstelegraph.com - July 12 at 8:25 PM
News IconStock on the Rise for the Quarter: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Engelwood Daily (NASDAQ:VTAE)
www.engelwooddaily.com - July 11 at 6:46 AM
News IconStock Rating Watch and Earnings Insight for Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Press Telegraph (NASDAQ:VTAE)
presstelegraph.com - July 11 at 6:46 AM
News IconWere Analysts Bullish Vitae Pharmaceuticals Inc (NASDAQ:VTAE) This Week? - Engelwood Daily (NASDAQ:VTAE)
www.engelwooddaily.com - July 10 at 7:01 AM
News IconCan Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Improve on the Earnings Front? - Engelwood Daily (NASDAQ:VTAE)
www.engelwooddaily.com - July 8 at 10:59 AM
News IconCompany Stock Focus for Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE): Which Way Will Shares Head? - Press Telegraph (NASDAQ:VTAE)
presstelegraph.com - July 8 at 10:59 AM
News IconVitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Stock Update: Check on Ratings and Target Price - Telanagana Press (NASDAQ:VTAE)
telanaganapress.com - July 6 at 6:46 AM
News IconHow Many Vitae Pharmaceuticals Inc (NASDAQ:VTAE)'s Analysts Are Bearish? - Press Telegraph (NASDAQ:VTAE)
presstelegraph.com - July 3 at 6:49 AM
News IconDafna Capital Management LLC Increased Vitae Pharmaceuticals INC (NASDAQ:VTAE) by $3.56 Million as Shares ... - Engelwood Daily (NASDAQ:VTAE)
www.engelwooddaily.com - July 2 at 10:44 AM
biz.yahoo.com logoVITAE PHARMACEUTICALS, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E (NASDAQ:VTAE)
biz.yahoo.com - June 30 at 4:12 PM
ftsenews.co.uk logoVitae Pharmaceuticals, Inc. (VTAE) Updated Price Targets - FTSE News (NASDAQ:VTAE)
www.ftsenews.co.uk - June 30 at 10:52 AM
News IconCheck on Share Volatility: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Engelwood Daily (NASDAQ:VTAE)
www.engelwooddaily.com - June 29 at 10:52 AM
News IconVitae Pharmaceuticals Incorporated (NASDAQ:VTAE) Short Interest Decreased By 8.81% - Press Telegraph (NASDAQ:VTAE)
presstelegraph.com - June 29 at 10:52 AM
News IconVitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Company Rating and Target Watch - Telanagana Press (NASDAQ:VTAE)
telanaganapress.com - June 29 at 10:52 AM
News IconShare Update and Earnings Review for Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Press Telegraph (NASDAQ:VTAE)
presstelegraph.com - June 27 at 6:43 AM

Social

Vitae Pharmaceuticals (NASDAQ:VTAE) Chart for Thursday, August, 25, 2016


Last Updated on 8/25/2016 by MarketBeat.com Staff